Amphstar Pharmaceuticals
AMPH · Pharmaceuticals
$25.14
3.5%Collegium Pharmaceutical
COLL · Pharmaceuticals
$22.96
2.3%The short version
- Collegium Pharmaceutical is the larger business, with $781M of revenue in fiscal 2025 against $720M for Amphstar Pharmaceuticals.
- Collegium Pharmaceutical grew revenue faster (23.6%, against −1.7%).
- Collegium Pharmaceutical kept more of each dollar of sales as operating profit (23.0% operating margin, against 19.5% operating margin).
- Collegium Pharmaceutical turned more of its sales into free cash flow (42.0% FCF margin, against 16.8% FCF margin).
- Collegium Pharmaceutical earned a higher return on the capital invested in it (53.4%, against 9.9%).
- Investors pay more for each dollar of Collegium Pharmaceutical’s earnings: a P/E of 18.5x against 14.9x for Amphstar Pharmaceuticals.
| Latest fiscal year | AMPH · FY25 | COLL · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.1B | $746M |
| Revenue | $720M | $781M |
| Free cash flow | $121M | $328M |
| Net income | $98.1M | $62.9M |
| Growth | ||
| Revenue growth | −1.7% | 23.6% |
| 5-year growth | 15.5% | 20.3% |
| Share count change | −7.4% | −1.8% |
| Profitability | ||
| Gross margin | 49.5% | 59.4% |
| Operating margin | 19.5% | 23.0% |
| Net margin | 13.6% | 8.1% |
| FCF margin | 16.8% | 42.0% |
| Return on capital | 9.9% | 53.4% |
| Return on equity | 12.9% | 23.7% |
| Balance sheet | ||
| Net debt | $339M | −$149M |
| Net debt / EBITDA | 1.7x | −0.4x |
| Dividends and buybacks | $75.6M | $25.1M |
| Valuation & quality | ||
| P/E | 14.9x | 18.5x |
| Piotroski F-score | 6 | 6 |
FY16
AMPH $255M
COLL $1.7M
FY17
AMPH $240M
COLL $28.5M
FY18
AMPH $295M
COLL $280M
FY19
AMPH $322M
COLL $297M
FY20
AMPH $350M
COLL $310M
FY21
AMPH $438M
COLL $277M
FY22
AMPH $499M
COLL $464M
FY23
AMPH $644M
COLL $567M
FY24
AMPH $732M
COLL $631M
FY25
AMPH $720M
COLL $781M
AMPH
COLL
FY16
AMPH 6.0%
COLL −5,498.7%
FY17
AMPH −0.5%
COLL −265.0%
FY18
AMPH −2.9%
COLL −7.4%
FY19
AMPH −0.0%
COLL −8.0%
FY20
AMPH 3.1%
COLL 18.1%
FY21
AMPH 16.0%
COLL 6.4%
FY22
AMPH 21.5%
COLL 7.2%
FY23
AMPH 30.6%
COLL 29.5%
FY24
AMPH 28.1%
COLL 26.9%
FY25
AMPH 19.5%
COLL 23.0%
AMPH
COLL
FY16
AMPH $17.2M
COLL −$75.5M
FY17
AMPH $4.1M
COLL −$68.0M
FY18
AMPH −$8.6M
COLL $164M
FY19
AMPH $0.2M
COLL $21.3M
FY20
AMPH $23.4M
COLL $88.4M
FY21
AMPH $70.5M
COLL $102M
FY22
AMPH $65.2M
COLL $123M
FY23
AMPH $145M
COLL $274M
FY24
AMPH $172M
COLL $203M
FY25
AMPH $121M
COLL $328M
AMPH
COLL
FY16
AMPH 3.7%
COLL —
FY17
AMPH −0.4%
COLL —
FY18
AMPH −2.1%
COLL —
FY19
AMPH −0.0%
COLL —
FY20
AMPH 1.4%
COLL —
FY21
AMPH 13.4%
COLL 10.4%
FY22
AMPH 20.9%
COLL 16.5%
FY23
AMPH 22.6%
COLL 68.7%
FY24
AMPH 16.4%
COLL 53.0%
FY25
AMPH 9.9%
COLL 53.4%
AMPH
COLL
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.